Listen to this article

The basics:

• Novo Nordisk introduces subscription pricing for Wegovy, lowering monthly costs for eligible self-pay patients
• Plans offered in 3-, 6- and 12-month terms, with deeper savings for longer commitments
• Program available through telehealth platforms including Ro, Weight Watchers, LifeMD, Hims & Hers, Sesame
• Move aims to improve affordability and adherence as demand for GLP-1 weight loss drugs grows

Novo Nordisk is launching a subscription plan for its blockbuster GLP-1 weight loss drug Wegovy. The debut offers lower monthly prices to eligible cash-paying patients.

Available through select telehealth providers, the new pricing model applies to both the injection and pill versions of the medicine, according to the Danish pharmaceutical company.

Patients can choose three-, six- or 12-month plans. Platforms such as Ro, Weight Watchers, LifeMD, Hims & Hers and Sesame will offer the plans, said Novo Nordisk.

The company with its U.S. headquarters in Plainsboro noted that the longer subscription periods offer lower monthly pricing. Novo Nordisk also said the prices will hold flat each month regardless of dose changes.

According to the pharma giant, the options are:

Wegovy pen (0.25 milligram, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg doses)

• Three-month subscription: $329/month, a savings of $240 per year
• Six-month subscription: $299/month, a savings of $600 per year
• 12 month subscription: $249/month, a savings of $1,200 per year

Wegovy pill (9 mg and 25 mg doses)

• Three-month subscription: $289/month, a savings of $120 per year
• Six-month subscription: $269/month, a savings of $360 per year
• 12 month subscription: $249/month, a savings of $600 per year

Additionally, Novo Nordisk said it will add the recently approved 7.2 milligram injection dose to the subscription program soon.

Patients can opt out of the subscription while it is active if they choose to stop the medication. The program is not available on the NovoCare direct-to-consumer pharmacy platform, but the company said it may add it at a later time, Novo Nordisk said.

‘A more manageable way’

Novo Nordisk said the first-of-a-kind program “is designed to reduce cost uncertainty and help people start and stay on FDA-approved obesity treatment.”

A semaglutide-based drug, the U.S. Food and Drug Administration first approved Wegovy in June 2021 specifically for chronic weight management in individuals who are obese or over-weight with at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.

Administered through injector pens in once-weekly dosing, Novo Nordisk says patients should pair the drug with diet and exercise changes to lose weight and keep it off.

The FDA approved the once-daily pill version of Wegovy in December 2025.

CNBC pointed to a 2025 study that estimated roughly 65% of patients with obesity stop taking GLP-1 drugs within a year due to facts such as difficulty accessing the therapy or gastrointestinal side effects.

Novo Nordisk Senior Vice President of Marketing & Patient Solutions Ed Cinca said, “The new Wegovy subscription program removes barriers, providing people who enroll a simple, affordable, and consistent way to start and stay on genuine, FDA-approved treatment.”

The new Wegovy subscription program removes barriers, providing people who enroll a simple, affordable, and consistent way to start and stay on genuine, FDA-approved treatment.
— Ed Cinca, senior vice president of marketing & patient solutions, Novo Nordisk

“By providing predictable monthly pricing, multi-month options, and access through trusted telehealth providers, this program aims to support a more manageable way for people to stay on treatment and focus on achieving meaningful, sustainable weight loss outcomes,” he said.

The race is on

Although the Wegovy tablet is gaining strong traction in the U.S. since it hit the market earlier this year, it’ll face competition from Eli Lilly’s newly approved oral version.

Compared with injectables, oral medications are cheaper to manufacture and generally easier for patients to administer. As a result, pharmaceutical companies are racing to bring weight loss pills to the GLP-1 space, which is expected to be worth $100 billion by the 2030s, CNBC noted.

According to Novo Nordisk, self-pay patients who do not enroll in a subscription can still access lower dose Wegovy pills (1.5 mg and 4 mg) for $149 per month. Starting in September, the 4 mg dose will rise to $199 per month, the company said.

In addition to working with select telehealth providers, Wegovy is available through a range of additional access points, including more than 70,000 U.S. pharmacies and NovoCare Pharmacy. Those with commercial insurance coverage can access Wegovy for as little as $25 per month through existing savings programs, the company said.